NCT07047885View on ClinicalTrials.gov

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

PHASE1RecruitingINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions

Cutaneous T Cell Lymphoma

Interventions

DRUG

Ropeginterferon alfa-2b

Will be administered via subcutaneous injection once every 2 weeks

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

PharmaEssentia

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER